Results 11 to 20 of about 8,840 (216)

Lupus and NMOSD: The Blending of Humoral Autoimmunity [PDF]

Case Reports in Rheumatology, 2020
Systemic lupus erythematous (SLE) is a chronic autoimmune disease that can target any organ of the body. It may coexist with other autoimmune neurologic conditions such as neuromyelitis optica spectrum disorder (NMOSD). NMOSD, previously known as Devic’s
Maria Goretti S. Ochi, Samantha C. Shapiro, Esther Melamed   +2 more
doaj   +4 more sources

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort [PDF]

Acta Neurologica Belgica, 2021
Abstract Purpose To emphasize physio-pathological, clinical and prognosis differences between conditions causing serious and sometimes very similar clinical manifestations: anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies related diseases, and seronegative NMOSD (neuromyelitis optica ...
Dauby, Solène, DIVE, Dominique, LUTTERI, Laurence, ANDRIS, Cécile, HANSEN, Isabelle, MAQUET, Pierre, LOMMERS, Emilie   +6 more
openaire   +4 more sources

Novel emerging treatments for NMOSD [PDF]

Neurologia i Neurochirurgia Polska, 2019
Neuromyelitis optica spectrum disorders (NMOSD) are inflammatory demyelinating diseases of the central nervous system (CNS) that cause optic neuritis, transverse myelitis, and some other CNS syndromes. Recently, diagnosis and understanding of these diseases has been markedly enhanced by the discovery that serum autoantibodies that target aquaporin-4 ...
Krzysztof, Selmaj, Igor, Selmaj
openaire   +4 more sources

Response to treatment in NMOSD: the Australasian experience

Multiple Sclerosis and Related Disorders, 2022
Neuromyelitis optica spectrum disorder (NMOSD) is associated with significant morbidity and mortality. Several therapies have been recommended for NMOSD and more recently clinical trials have demonstrated efficacy for three monoclonal antibody therapies.
Clarke, Laura, Bukhari, Wajih, McCombe, Pamela A., Sutton, Ian, Boggild, Mike, Brownlee, Wallace, Carroll, William M., Hodgkinson, Suzanne, Macdonell, Richard A.L., Mason, Deborah F., Pereira, Jennifer, Slee, Mark, O'Gorman, Cullen M., Das, Chandi, Henderson, APD, Kermode, AG, Lechner-Scott, Jeannette, Waters, P, Sun, J, Broadley, SA, Khalilidehkordi, Elham, Arnett, Simon, Woodhall, Mark, Prain, Kerri M., Parratt, John D.E., Barnett, Michael H., Marriott, Mark P.   +26 more
openaire   +6 more sources

Adverse Events in NMOSD Therapy

International Journal of Molecular Sciences, 2022
Neuromyelitis optica spectrum disorders (NMOSD) are rare neurologic autoimmune diseases that have a poor prognosis if left untreated. For many years, generic oral immunosuppressants and repurposed monoclonal antibodies that target the interleukin-6 pathway or B cells were the mainstays of drug treatment.
Katrin Giglhuber, Achim Berthele
openaire   +3 more sources

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

CNS Neuroscience & Therapeutics, 2022
AbstractNeuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune inflammatory demyelinating disorder of the central nervous system (CNS), which is a severely disabling disorder leading to devastating sequelae or even death. Repeated acute attacks and the presence of aquaporin‐4 immunoglobulin G (AQP4‐IgG) antibody are the typical ...
Mingchao Shi, Fengna Chu, Tao Jin, Jie Zhu   +3 more
openaire   +3 more sources

NMOSD and MOGAD: an evolving disease spectrum

Nature Reviews Neurology
Neuromyelitis optica (NMO) spectrum disorder (NMOSD) is a relapsing inflammatory disease of the CNS, characterized by the presence of serum aquaporin 4 (AQP4) autoantibodies (AQP4-IgGs) and core clinical manifestations such as optic neuritis, myelitis, and brain or brainstem syndromes.
Akiyuki Uzawa, Frederike Cosima Oertel, Masahiro Mori, Friedemann Paul, Satoshi Kuwabara   +4 more
openaire   +3 more sources

The clinical profile of NMOSD in Australia and New Zealand [PDF]

, 2020
Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and New Zealand populations with the aim ...
Prain, Kerri M, Arnett, Simon, McCombe, Pamela A, Stankovich, James, Woodhall, Mark, Henderson, Andrew PD, Pollard, John D, Brew, Bruce J, Heard, Robert, Butzkueven, Helmut, Willoughby, Ernest, Parratt, John, Yiu, Eppie M, Bukhari, Wajih, Khalilidehkordi, Elham, Boggild, Mike, Wong, Richard C, Hawke, Simon, Broadley, Simon A, Boundy, Karyn, Vincent, Angela, Shaw, Cameron, Slee, Mark, Blum, Stefan, Bundell, Christine S, Jimenez-Sanchez, Sofia, Wilson, Robert J, Silvestrini, Roger, Coulthard, Alan, Lynch, Christopher, Mason, Deborah F, Vucic, Steve, Dale, Russell C, Marriott, Mark P, Sutton, Ian, Macdonnell, Richard AL, Gillis, David, Brilot, Fabienne, Spies, Judith, Waters, Patrick, Fulcher, David, Pereira, Jennifer, Brownlee, Wallace, Lechner-Scott, Jeannette, Fabis-Pedrini, Marzena J, Kornberg, Andrew J, Barnett, Michael H, Lin, Ming-Wei, Chen, Celia, Walsh, Michael, Carroll, William M, Kermode, Allan G, King, John, Bhuta, Sandeep, Kilpatrick, Trevor J, Das, Chandi, Abernethy, David, Hodgkinson, Suzanne, Reddel, Stephen W, Kneebone, Chris, Ramanathan, Sudarshini, Clarke, Laura, Dear, Keith, Taylor, Bruce V, O'Gorman, Cullen, Heshmat, Saman   +65 more
core   +4 more sources

TDP43 augments astrocyte inflammatory activity through mtDNA-cGAS-STING axis in NMOSD

Journal of Neuroinflammation
Abnormality in transactivating response region DNA binding protein 43 (TDP43) is well-recognized as the pathological hallmark of neurodegenerative diseases.
Zhuhe Liu, Yunmeng Bai, Bingtian Xu, Haixia Wen, Kechun Chen, Jingfang Lin, Yuanyuan Wang, Jiangping Xu, Haitao Wang, Fudong Shi, Jigang Wang, Honghao Wang   +11 more
doaj   +2 more sources

The Comprehensive Live Cell-Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a devastating neurological disease that lacks serological biomarkers that can accurately reflect disease activity. We established a live cell‐based assay (LCBA) using serum with endogenous complement to quantify the overall cytotoxicity, offering a novel functional tool for monitoring
Xu X, Ding J, Du Y, Luo G, Li J, Liu R, Xu X, Li X, Li M, Jiang W, Yang C.   +10 more
europepmc   +2 more sources